# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY AND INSTRUMENT

I Background Information:

A 510(k) Number K242095   
B Applicant Beckman Coulter Inc.   
C Proprietary and Established Names Access Toxo IgM II   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LGD</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3780 -Toxoplasma GondiiSerological Reagents</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of new device   
B Measurand: IgM antibodies to Toxoplasma gondii   
C Type of Test: Chemiluminescent Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Access Toxo IgM II assay is a paramagnetic-particle chemiluminescent immunoassay for the qualitative detection of Toxoplasma gondii-specific IgM antibody in adult human serum and plasma using the Access Immunoassay Systems.

The Access Toxo IgM II assay is presumptive for the diagnosis of acute, recent, or reactivated Toxoplasma gondii infection in males and pregnant or non-pregnant females. It is recommended this assay be performed in conjunction with a Toxoplasma gondii-specific IgG antibody assay.

Note: This assay has not been cleared/approved by the FDA for the screening of blood or plasma donors in the United States.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

Performance has not been established for the use of bodily fluids other than human serum or plasma.

# D Special Instrument Requirements:

DxI 9000 Access Immunoassay Analyzer

# IV Device/System Characteristics:

# A Device Description:

The Access Toxo IgM II assay is a paramagnetic-particle chemiluminescent immunoassay for the qualitative detection of Toxoplasma gondii-specific IgM antibody in adult human serum and plasma using the Access Immunoassay Systems.

The Access Toxo IgM II assay consists of the reagent pack, calibrators, and quality controls (QCs), packaged separately. Other items needed to run the assay include substrate and wash buffer.

# B Principle of Operation:

The Access Toxo IgM II assay is an immunoenzymatic assay and uses the immunocapture principle. The sample to be tested is added to a reaction vessel with paramagnetic particles coated with human IgM-specific sheep polyclonal antibody as capture antibody. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then a complex formed with T. gondii antigen and $T .$ .

gondii (P30)-specific monoclonal antibody that has been labeled with alkaline phosphatase is added to the reaction vessel. After a second incubation and a second washing, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The photon production is a function of the amount of enzyme conjugate present at the end of the reaction. The light quantity measured for a sample allows a determination of the presence of $T .$ gondii-specific IgM antibody, by comparison with a cut-off value defined during the assay calibration on the instrument. If the light production is equal or greater than the cut-off value, the sample is considered reactive in the Access Toxo IgM II assay.

The cutoff for non-reactivity is $0 . 8 \ : \mathrm { S } / \mathrm { C O }$ and reactivity is $1 . 0 0 \mathrm { S } / \mathrm { C O }$ . Results between 0.8 – 1.0 S/CO (equivocal zone) should be confirmed by testing a new sample 10 to 20 days later. The Access Toxo IgM II assay results interpretation is presented in Table 1.

Table 1: Access Toxo IgM II Results Interpretation   

<table><tr><td rowspan=1 colspan=1>Readout in S/CO</td><td rowspan=1 colspan=1>Interpretation</td></tr><tr><td rowspan=1 colspan=1>S/CO &lt; 0.8</td><td rowspan=1 colspan=1>Non-Reactive</td></tr><tr><td rowspan=1 colspan=1>0.8 ≤ S/CO&lt; 1.0</td><td rowspan=1 colspan=1>Equivocal</td></tr><tr><td rowspan=1 colspan=1>S/CO ≥ 1.0</td><td rowspan=1 colspan=1>Reactive</td></tr></table>

# V Substantial Equivalence Information:

A Predicate Device Name(s): Access Toxo IgM II Assay

B Predicate 510(k) Number(s): K003259

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">K242095Candidate Device</td><td colspan="1" rowspan="1">K003259Predicate</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Access Toxo IgM II</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indicationsfor Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">The Access Toxo IgM II assay is aparamagnetic-particle chemiluminescentimmunoassay for the qualitative detectionof Toxoplasma gondii-specific IgMantibody in adult human serum andplasma using the Access ImmunoassaySystems.The Access Toxo IgM II assay ispresumptive for the diagnosis of acute,</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">recent, or reactivated Toxoplasma gondiiinfection in males and pregnant or non-pregnant females. It is recommended thisassay be performed in conjunction with aToxoplasma gondii-specific IgG antibodyassay.Note: This assay has not beencleared/approved by the FDA for thescreening of blood or plasma donors inthe United States.</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">IgM antibody to T. gondii</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-step (sandwich) chemiluminescenceimmunoassay</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Chemiluminescent</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Automated</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Utilizes a stored calibration curve</td></tr><tr><td colspan="1" rowspan="1">Calibrationfrequency</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">28 days</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum and plasma</td></tr><tr><td colspan="1" rowspan="1">ResultsInterpretation</td><td colspan="1" rowspan="1">S/CO &lt; 0.8 Non-Reactive0.8 ≤ S.CO &lt; 1.0 EquivocalS/CO ≥ 1.0 Reactive</td><td colspan="1" rowspan="1">S/CO &lt; 1.0 Non-Reactive0.8 ≤ S.CO &lt; 1.0 Grey ZoneS/CO ≥ 1.0 Reactive</td></tr><tr><td colspan="1" rowspan="1">CaptureAntibody</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Anti-human IgM antibody (sheep)</td></tr><tr><td colspan="1" rowspan="1">DetectionAntibody</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Inactivated T. gondii Ag - T. gondii(P30)-specific mouse monoclonalantibody conjugated to alkalinephosphatase (bovine) complex</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">28 days after opening, 2-10°C</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">GeneralDeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="1" rowspan="1">Lumi-Phos PRO substrate</td><td colspan="1" rowspan="1">Access Substrate</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">DxI 9000 AccessImmunoassay Analyzer</td><td colspan="1" rowspan="1">Access Immunoassay System</td></tr></table>

The following Clinical and Laboratory Standards Institute (CLSI) guidelines were used:   
• CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved   
Guideline   
• CLSI EP12-Ed 3: Evaluation of Qualitative Binary Output Examination Performance; Approved   
Guideline

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

a) Within-Laboratory Precision: A 20-day within-laboratory precision study was conducted using 3 lots of the Access Toxo IgM II reagents, three lots of the Access Toxo IgM II calibrators and 3 DxI 9000 Access Immunoassay Analyzer systems. Four human serum samples were tested in 2 replicates at 2 runs per day over 20 days using 3 reagent lot/calibrator lot combinations, where a unique reagent lot and calibrator lot are paired. The data were analyzed for repeatability (within-run), between-run, between-day, and withinlaboratory precision. Within-laboratory precision data summary is shown in Table 2.

Table 2: Access Toxo IgM II Within-Laboratory Precision   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(S/CO)</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between -LotandInstrumenta</td><td rowspan=1 colspan=2>OverallPrecisionb</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>0.151</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.160</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.329</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>8.76</td><td rowspan=1 colspan=1>0.207</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.169</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.213</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.368</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.502</td><td rowspan=1 colspan=1>5.7</td></tr></table>

a Access Toxo IgM II reagent lot, Access Toxo IgM II calibrator lot and DxI 9000 instruments are confounded, and the confounding effect is represented by between-lot and instrument. b Overall within-laboratory variability includes within-run, between-run, between-day, and between-lot variance components.

b) Reproducibility (between-Instrument Precision): An additional precision study was conducted over 5-day by testing four serum samples on $3 \mathrm { ~ D x I ~ } 9 0 0 0$ Access Immunoassay Analyzers in an internal site. The samples were tested with 3 lots of Access Toxo IgM II reagents, and 1 lot of Access Toxo IgM II calibrator on each instrument with 5 replicates per run and 1 run per day over 5 days. Between-instrument reproducibility data is shown in Table 3.

Table 3: Access Toxo IgM II Assay Reproducibility (Between-Instrument Precision)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(S/CO)</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between-Day/Runsa</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenReagent lot</td><td rowspan=1 colspan=2>Reproducibilityb</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>4.83</td><td rowspan=1 colspan=1>0.117</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.154</td><td rowspan=1 colspan=1>3,2</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.199</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>9.26</td><td rowspan=1 colspan=1>0.210</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.316</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.170</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.410</td><td rowspan=1 colspan=1>4.6</td></tr></table>

a Days and runs are confounded. b Reproducibility includes within-run, between-run, between-day, and between-lot variance components.

c) Reproducibility (between-site precision): Refer to K002453 and K031506.

2. Linearity: Not applicable

3. Analytical Specificity/Interference: Refer to K002453.

4. Assay Reportable Range: Not applicable

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not applicable

6. Detection Limit: Not applicable

7. Assay Cut-Off: Refer to K002453.

8. Carry-Over: Not applicable

# B Comparison Studies:

1. Comparison of Access Toxo IgM II assay on the Access 2 Immunoassay Analyzer to the DxI 9000 systems:

A method comparison study was conducted to compare the performance of the Access Toxo IgM II assay on DxI 9000 Access Immunoassay Analyzer to the Access Toxo IgM II assay on the Access 2 Immunoassay System. A total of 152 native serum samples were tested. Positive percent agreement (PPA) and negative percent agreement (NPA) between the DxI 9000 Immunoassay Analyzer and the Access 2 Immunoassay system was calculated for the Access Toxo IgM II assay and shown in Table 4.

Table 4: Performance Agreement of Access Toxo IgM II assay on the Access 2 Immunoassay Analyzer to the DxI 9000 System $\mathrm { ( n { = } 1 5 2 ) }$ )   

<table><tr><td rowspan=2 colspan=2>Access Toxo IgM ⅡI</td><td rowspan=1 colspan=4>Access 2 Immunoassay Analyzer</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>Grey Zone</td><td rowspan=1 colspan=1>Non-reactive</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=4 colspan=1>DxI9000System</td><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Non-Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>107</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>152</td></tr><tr><td rowspan=1 colspan=2>Positive PercentAgreement (PPA)</td><td rowspan=1 colspan=1>100.00% (41/41)</td><td rowspan=1 colspan=3>95% CIa = 91.43% to 100.00%</td></tr><tr><td rowspan=1 colspan=2>Negative PercentAgreement (NPA)</td><td rowspan=1 colspan=1>100.00% (107/107)</td><td rowspan=1 colspan=3>95% CIa = 96.53% to 100.00%</td></tr></table>

$9 5 \%$ CI for PPA and NPA were estimated using the Wilson score method.

2. Matrix Comparison: Refer to K003259.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): For clinical agreement study refer to K002453.

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

Not applicable

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.